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Abstract 
Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is rare and knowledge on its 
underlying genetics is limited. A few somatic mutations have been reported in four seroma-
associated cases. Here, we characterized paired BI-ALCL samples from a patient whose disease 
presented as a solid tumour and recurred as an in situ capsular lesion. We identified two 
pathogenic gain-of-function hotspot mutations in the kinase domain of JAK1 (G1097V) and in 
the SH2 domain of STAT3 (S614R) in both specimens, demonstrated nuclear p-STAT3 in the 
lymphoma cells and found no rearrangements of DUSP22, TP63 or VAV1. Our findings reinforce 
the notion that mutation-induced activation of the JAK/STAT pathway represents a recurrent 
oncogenic mechanism in both clinical presentations of BI-ALCL; moreover the co-occurrence of 
dual JAK1/STAT3 mutations as observed in our case suggests pathogenic mechanisms 
overlapping with those of systemic ALK-negative ALCL. 
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Introduction 
Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) recently described as a 
distinctive form of CD30+ anaplastic large-cell lymphoproliferation, was introduced as a new 
provisional T-cell lymphoma entity in the 2017 WHO classification of haematological 
malignancies [1]. While the morphological and immunophenotypical features of BI-ALCL are 
indistinguishable from those of other ALK-negative ALCL, the specificity of BI-ALCL is its clinical 
presentation adjacent to a breast implant. Most cases confined to the periprosthetic effusion 
and capsule (seroma or « in situ » lymphoma) have excellent outcomes, and a minority of 
patients present with a breast tumour mass, which is an adverse prognostic factor [2,3]. 
Yet, information on the genetic alterations associated to BI-ALCL is essentially limited to 
data derived from a few lymphoma specimens, all with seroma-associated presentation 
(summarized in Table 1). [4] [5] [6] [7] Here we report genetic findings in paired BI-ALCL samples 
of a patient whose disease presented as a solid tumour and recurred as an in situ capsular 
lesion. 
Methods 
Both specimens were routinely processed after formalin fixation and paraffin embedding in the 
Department of Pathology of the Institute Jules Bordet (Brussels, Belgium). Immunophenotyping 
was performed with routinely used antibodies on Ventana Benchmark/Ultra instruments. 
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Immunohistochemistry for phospho-STAT3 (Tyr205) was performed with the D3A4 rabbit
monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA ; ref. 9145) diluted at 1/100
4 
Fluorescent in situ hybridization 
Laboratory-developed FISH probes (Institute of Pathology, Lausanne) using bacterial artificial 
chromosome (BAC) combinations were used to explore rearrangements of DUSP22/IRF4, TP63 
and VAV1.  For DUSP22/IRF4, break-apart probe consisted of telomeric RP3-416J7, labeled with 
Spectrum Orange; and centromeric RP11-615C17 and CTD-3139L20 labeled with Spectrum 
Green. For TP63, break-apart probe consisted of telomeric RP11-24F1, labeled with Spectrum 
Orange; and centromeric RP11-53D15 labeled with Spectrum Green. For VAV1, break-apart 
probe consisted of telomeric RP11-828J24, RP11-809P6 and RP11-134L9 labeled with Spectrum 
Green; and RP11-876D1, CTD-3131P and RP11-1137G4 labeled with Spectrum Orange. 
Targeted sequencing 
DNA extracted from primary and recurrent FFPE tumour samples after enrichment by scraping 
under microscopic control, was used to prepare DNA libraries with the KAPA HyperPlus library 
preparation kit (Roche). Target enrichment of the DNA libraries was performed by hybridization 
capture using a custom design of xGen® Lockdown® Probes (Integrated DNA Technologies) 
covering the full coding sequences of 26 genes recurrently mutated in various mature T-cell 
neoplasms (ARID1A, ATM, BCOR, CARD11, CCR4, CD28, CTNNB1, DDX3X, DNMT3A, FYN, IDH2, 
IRF4, JAK1, JAK3, KMT2D, PIK3CD, PLCG1, PRKCB, RHOA, SETD2, STAT3, STAT5B, TET2, 
TNFRSF1B, TP53, VAV1). Enriched libraries were sequenced on a MiSeq instrument (Illumina). 
Raw reads were aligned to the hg19 human genome assembly using BWA aligner and further 
processed following GATK best practices (https://software.broadinstitute.org/gatk/best-
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and incubated overnight at 4°C after 3 minutes antigen retrieval in EDTA pH 9 in a pressure
cooker.
5 
practices/). The list of variants was obtained combining calls from both VarScan (2.4.2) and 
MuTect2 variant callers packages using default settings. Variants were further filtered based on 
local coverage (>50), number of altered reads (>5), allele frequency (>1%) and strand bias. 
Case report 
The woman born in 1943 had elective bilateral insertion of silicone-filled breast implants 
(McGhan) in 1992 for cosmetic reasons. She presented in May 2011 with a right breast mass; 
MRI imaging showed a 3.9 cm solid lesion, no periprosthetic effusion, and enlarged right axillary 
lymph nodes. A PET CT-scan demonstrated a voluminous hypermetabolic lesion (SUV 13.3) in 
the lower right breast adjacent to the prosthesis and multiple slightly hypermetabolic lymph 
nodes in the right axilla (Figure 1). A tumorectomy was performed which comprised a 2.8 cm 
solid and partially necrotic infiltrating tumour made up of cohesive sheets of large anaplastic 
lymphoid cells (Figure 2A-B), abutting to the resection margin. By immunohistochemistry the 
tumour cells were strongly positive for CD30, positive for CD8 and CD45 RO, negative for ALK, 
EMA, CD2, CD3, CD4, CD5, CD7, CD15, CD20, CD45, CD56, and had an activated cytotoxic 
phenotype (granzyme-B+, perforin+) (Figure 2 C-E). A staging bone marrow biopsy was negative. 
The patient was treated with 5 cycles of CHOP (cyclophosphamide, daunorubicin, oncovin, 
prednisone) resulting in complete metabolic response. Consolidation with 2 cycles of high-dose 
methotrexate 3 g/m² was subsequently administered, followed by autologous stem cell 
transplantation after BEAM conditioning in November 2011. In 2012 both prostheses were 
replaced by silicone-filled implants with biocell-textured shell (Allergan). In 2015 MRI 
demonstrated a rupture of the right prosthesis, and both prostheses were removed. The right 
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6 
periprosthetic capsule was macroscopically irregular and gritty and on histology showed a 
proliferation of large anaplastic cells confined to the surface and admixed with fibrin (Figure 2F-
G). The immunophenotype was similar to that of the 2011 lesion, except for loss of CD8 
expression and detectable EMA expression.  An identical monoclonal rearrangement of TRG and 
TRB genes was demonstrated in both specimens. The patient did not receive further treatment 
and was last seen in July 2017, with no evidence of recurring disease. 
The patient consented to further genetic analyses. FISH studies with break-apart probes 
for DUSP22/IRF4, TP63 and VAV1 loci showed no evidence of rearrangement (Figure 2H-I).  We 
performed targeted deep sequencing analysis of both primary and recurrent tumors, using a 
panel of 26 genes relevant to T-cell lymphoma oncogenesis. Two pathogenic hotspot mutations, 
one in the kinase domain of JAK1 (c.3290G>T (p.G1097V)) and the other in the SH2 domain of 
STAT3 (c.1840A>C (p.S614R)), were detected in both specimens. Moreover, an additional JAK1 
truncating mutation (c.549dupT (p.D184*)) was detected in the first tumour only. Reflecting the 
presumed mutation-induced STAT3 activation, immunohistochemistry showed high levels of 
nuclear pSTAT3 expression in most tumour cells (Figure 2J). 
Discussion 
We report a patient with breast implants who developed BI-ALCL in the form of an unusual 
tumor mass presentation, was set to remission after surgical resection and systemic and 
intensive systemic treatment, and recurred four years later with a seroma-associated in situ 
capsular lesion in the same breast. The clinical management of the patient in 2011 was not in 
line with the current recommendations that would require upfront removal of the prosthetic 
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7 
implants, and indeed the delay for prosthesis resection could have been responsible for the 
tumor recurrence, since one can suspect that the capsular involvement might have been 
present since the very beginning, although at an infra-clinical state with no evidence of effusion. 
Both clonality studies and targeted deep sequencing results, provided compelling evidence that 
the solid and seroma-associated lesions represented an identical clone, qualifying the second 
lesion as tumour recurrence. The tumor at presentation likely represents clonal evolution from 
a precursor lacking the second JAK1 mutation, and the recurrence evolved from the latter. 
Very limited information is available in the literature regarding the genetic lesions 
underlying BI-ALCL (Table 1). [4] [5] [6] [7]  In total, karyotypes from three cell lines derived 
from BI-ALCLs and mutational analysis of seven primary tumor samples have been reported.  
The BI-ALCL-derived cell lines had markedly abnormal complex karyotypes with a near-diploid or 
a hypertriploid pattern)[4,5]. In contrast, of the seven cases of BI-ALCL that were successfully 
analyzed by whole exome or targeted next-generation sequencing using a large panel of 465 
cancer-associated genes, only four showed a small number of somatic variants, and three of the 
five cases successfully analyzed with a large cancer-oriented sequencing panel were wild-type 
for all tested genes [6] [7]. Strikingly, two of the four cases harbored a STAT3 S614R variant (as 
the sole abnormality in one case and in combination with pathogenic TP53 and SOCS1 
mutations in the other), and another case harbored JAK1 (G1097V) somatic variant, indicating 
recurrent JAK/STAT mutations in BI-ALCL.  The S614R variant of STAT3 is known as a gain-of 
function variant and has a been found in a variety of T-cell neoplasms including T-LGL leukemia, 
extranodal NK/T-cell lymphoma, and systemic ALK-negative ALCL [8].  The JAK1 G1097V variant 
is also likely activating, since JAK1 mutants at the 1097 position reported in other ALK-negative 
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8 
ALCLs have activating function [9]. Accordingly, functional studies on the BI-ALCL cell lines 
showed evidence of STAT3 activation, and the pharmacological inhibition of STAT3 induced in 
vitro cell death [5]. 
Our case was characterized by coexistent JAK1 G1097V and STAT3 S614R mutations. 
While mutation-induced activation of the JAK/STAT pathway constitutes a recurrent oncogenic 
mechanism in a variety of T-cell malignancies [10-14], the co-occurrence of dual JAK1/STAT3 
mutations as observed in this BI-ALCL case represents a peculiar mutational pattern that yet has 
been reported only in a subset of nodal ALK-negative ALCLs [9], suggesting that the pathogenic 
mechanisms operating in BI-ALCL overlap with those of systemic ALK-negative ALCLs. The 
significance of the additional JAK1 truncating mutation found in the first tumour only is 
uncertain: similar mutations in gynecological tumours might interfere with IFNγ-mediated 
mechanisms of immune surveillance[15], but their impact in haematological neoplasias is 
unknown. Moreover, the same mutational pattern in the paired samples in this case indicates 
that the two types of clinical presentations of BI-ALCL (as a tumour or in association to a 
seroma) may not reflect molecularly distinct subtypes. Interestingly, including this case, the 
JAK1 G1097V and STAT3 S614R mutations were found in two and three BI-ALCL cases, 
respectively (Table 1). Since numerous other hotspot mutations in these genes are found in 
other haemopathies [8], despite the small number of BI-ALCL cases yet analyzed, it might be 
suggested that JAK1 G1097V and STAT3 S614R variants found by us and others could represent 
preferential recurrent drivers in this disease. 
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Table 1 
Summary of published genetic and molecular features of BI-ALCL specimens 
Reference Clinical features Specimen Analysis Results Comments 
Patient 1 - 
Lechner MG et al. 
Cancer 2011 
F/42 yrs-old; right recurring effusion, 
3.5 years after cosmetic insertion of 
implants; treated with surgery 
(bilateral implant removal 
+capsulectomy) and radiation 
therapy; in remission @ 6 years 
T-cell breast 
lymphoma (TLBR)-1 
cell line established 
from culture of the 
original tumor on a 
stromal feeder layer 
in the presence of IL-
2 
Conventional 
cytogenetics 
Complex karyotype: partial trisomy 2, 
addition involving 5p, deletion of 10p, 
unbalanced translocation between 
chromosomes 12 and 17, and monosomy 
16 and 20; presence of subclonal 
populations with the addition of unknown 
genetic material to the short arm of 
chromosomes 13, 15 and 15 
All three TLBR cell lines showed: 
increased levels of cleaved, 
activated NOTCH1; and 
activation of STAT3 signaling 
(nuclear expression of pSTAT3) 
and sensitivity to 
pharmacological STAT3 
inhibition in vitro. 
Blombery P et al. 
Haematologica 
2016 
Id. Effusion cytology 
fluid (and uninvolved 
bone marrow as 
germline control) 
Whole exome 
sequencing (mean 
target coverage 
113x for tumor 
DNA) 
Somatic mutation 
STAT3 S614R (c1840A>C) 
Copy number changes: 
1p and 10p copy number losses, 19p copy 
number gain 
Pathogenic gain-of-function 
mutation inducing STAT3 
activation 
Patient 2 - 
Lechner MG et al. 
Clin Cancer Res 
F/43 yrs-old; unilateral recurring 
effusion, after cosmetic insertion of 
implants; treated with surgery 
TLBR-2 cell line 
established from 
culture of the 
Conventional 
cytogenetics 
Hypertriploid complex karyotype with a 
modal number of chromosomes of 76, gains 
of chromosomes 1, 2, 5, 6, 10, 11, 14, 17, 
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11 
2012 (bilateral implant removal + 
capsulectomy); early local 
recurrence and distant 
dissemination of disease, resistant 
to chemotherapy; dead of disease @ 
9 months 
original tumor in the 
presence of IL-2 
and clonal loss of one copy of chromosome 
18, relative to a triploid genome. 
Patient 3 - 
Lechner MG et al. 
Clin Cancer Res 
2012 
F/45 yrs-old; unilateral recurring 
effusion, after cosmetic insertion of 
implants; treated with surgery 
(bilateral implant removal + 
capsulectomy) and radiation 
therapy; in remission @ 14 months 
TLBR-3 cell line 
established from 
culture of the 
original tumor in the 
presence of IL-2 
Conventional 
cytogenetics 
Hypertriploid complex karyotype with a 
modal number of chromosomes of 81, gains 
of chromosomes X, 2, 5, 7, 8, 10, 11, 12, 14, 
19, 20, 21 and 22, and loss of one copy of 
chromosomes 9, 16 and 17, relative to a 
triploid genome. 
Patient 4 -
Blombery P et al. 
Haematologica 
2016 
F/56 ys-old; left effusion 7 years 
after cosmetic insertion of implants; 
treated with surgery (implant 
removal + capsulectomy); in 
remission @6 months 
Effusion cytology 
fluid (and germline 
control) 
Whole exome 
sequencing (mean 
target coverage 
145x for tumor 
DNA) 
Somatic mutation 
JAK1 G1097V (c.3290_3291delinsTT) 
No copy number changes 
Probably pathogenic mutation 
affecting a codon frequently 
mutated in ALK-negative 
systemic ALCL, and other 
variants resulting from amino 
acid changes at this site result in 
constitutive JAK1 activation. 
Patient 5- F/54 yrs-old; right effusion 5 years Microdissected Targeted deep Somatic mutation Inactivating nonsense mutation 
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12 
Di Napoli A et al. 
British J Haematol 
after reconstructive insertion of 
implant (invasive ductal breast 
carcinoma) 
tumor cells of FFPE 
BI-ALCL samples and 
matched germline 
DNA 
sequencing using a 
panel of 465 
cancer-associated 
genes (average 
read depth 400x) 
DNMT3A W176X (c.528G>A) (VAF 39%) 
Copy number changes not analyzed 
of DNMT3. 
Patient 6- 
Di Napoli A et al. 
British J Haematol 
F/47 yrs-old; left effusion and 
contralateral axillary lymph node 
after reconstructive insertion of 
implant (breast cancer) 
Microdissected 
tumor cells of FFPE 
BI-ALCL samples and 
matched germline 
DNA 
Targeted deep 
sequencing using a 
panel of 465 
cancer-associated 
genes (average 
read depth 400x) 
Somatic mutations 
SOCS1 P83fs (c.248_293del) (VAF 10%) 
STAT3 S614R (c.1840A>C) (VAF 32%) 
TP53 D259Y (c.775G>T) (VAF 37%) 
Copy number changes not analyzed 
Coexisting gain-of-function 
mutation of STAT3 and 
deleterious loss-of-function of 
SOCS1 (negative feed-back 
regulator of the JAK/STAT 
pathway) likely converging to 
activate the JAK/STAT pathway 
Patient 7 - 
Letourneau A et 
al. current report 
F/68 yrs-old; right breast mass and 
homolateral enlarged axillary lymph 
node, without effusion, 9 years after 
cosmetic insertion of implants; 
treated with surgery (tumorectomy 
without implant removal), and high-
dose chemotherapy + autologous 
stem cell transplantation; followed 
by removal of implants and 
Microdissected 
tumor of FFPE breast 
tumorectomy 
Targeted deep 
sequencing using a 
panel of 26 genes 
relevant to T-cell 
lymphomagenesis 
(mean  read 
coverage  946X) 
Mutations 
JAK1 D184X (c.549dupT) (VAF 16%) 
JAK1 G1097V (c.3290G>T) (VAF 45%) 
STAT3 S614R (c.1840A>C) (VAF 26%) 
FISH analyses: no rearrangement of 
DUSP22/IRF4, TP63 and VAV1 loci 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
reinsertion of new prostheses 
Letourneau A. et 
al. current report 
Rupture of  the right implant 3 years 
later; treated with surgery (implant 
removal + capuslectomy); in 
remission @6 years after initial 
diagnosis 
Microdissected 
tumor of FFPE 
implant 
capsulectomy 
Targeted deep 
sequencing using a 
panel of 26 genes 
relevant to T-cell 
lymphomagenesis 
(mean  read 
coverage  1517X) 
Mutations 
JAK1 G1097V (c.3290G>T) (VAF 72%) 
STAT3 S614R (c.1840A>C) (VAF 26%) 
Same TCR rearrangement as in 
the tumor specimen. 
Disappearance of the JAK1 
D184X variant and increase VAF 
of the JAK1G1097V variant 
suggest loss of the allele 
harboring the deleterious 
mutation. 
VAF: variant allele frequency 
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Legend to Figures 
Figure 1 
PET-CT scan at diagnosis showing a hypermetabolic mass adjacent to the right breast implant on 
a frontal section. 
Figure 2 
 (A-B) BI-ALCL at presentation consisting of an infiltrative and partially necrotic (*) tumor mass 
composed of cohesive large anaplastic cells (haematoxylin and eosin); (C-E) 
immunohistochemical stainings of the tumor cells showing strong positivity for CD30 (C) and 
granzyme B (D), and weak positivity for CD8 (E) (immunoperoxidase); (F-G) recurrent “in situ” 
BI-ALCL consisting of an anaplastic cell proliferation associated to fibrin at the surface of the 
pseudocapsule (haematoxylin and eosin); (H-I) FISH analyses using break-apart probes for the 
DUSP22/IRF4 locus (H) and TP63 locus (I) showing colocalized signals only, indicative of the 
absence of rearrangements; (J) immunohistochemical staining showing nuclear expression of 
pSTAT3 (Tyr705) (immunoperoxidase). 
Notes 
AL and DM performed research; MM and RD contributed essential clinical information; BB and 
EM analysed the data and wrote the paper; LDL designed research and wrote the paper. 
Compliance with ethical standards. 
No funding. 
The authors declare no conflict of interest. 
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